Want to see SONX full AI Analyst Report?
SONX Stock Chart & Stats
$1.01
$0.00(0.00%)
At close: 4:00 PM EDT
$1.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $1.01
Previous CloseN/A
Volume1.00
Average Volume (3M)389.00
Market Cap
$235.07K
Enterprise Value$6.93
Total Cash (Recent Filing)$11.63M
Total Debt (Recent Filing)$18.93M
Price to Earnings (P/E)―
Beta-1.29
Next Earnings
Mar 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding427,401
10 Day Avg. Volume222
30 Day Avg. Volume389
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.05
P/FCF Ratio-0.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46.56
Revenue Forecast (FY)$42.30M
Bulls Say, Bears Say
Bulls Say
Improving Loss ProfileThe substantial reduction in net losses indicates meaningful cost control and/or mix improvement. If maintained, this trend could extend the company’s funding runway and improve its path toward sustainable profitability, despite earnings remaining negative.
Debt ReductionLower debt reduces interest and refinancing pressure and can improve financial flexibility over the medium term. Although capitalization remains weak, debt reduction provides a more manageable liability base if operating performance continues to improve.
Recurring Consumables ModelThe installed-base model can generate recurring procedure-related revenue after capital consoles are placed with practices. Greater utilization of the existing system base could improve revenue visibility and customer lifetime value without requiring a new console sale for every procedure.
Bears Say
Revenue ContractionTwo consecutive years of declining revenue raise concerns about product adoption, procedure volumes, or sales execution in a medical-device business. Persistent contraction could limit operating leverage and make it harder for recent cost improvements to translate into durable profitability.
Negative Stockholders' EquityNegative equity signals substantial accumulated losses and weak capitalization, reducing the company’s balance-sheet cushion. This may constrain strategic flexibility and increase dependence on financing or other capital support if losses or cash usage continue.
Persistent Negative Cash FlowDespite improved cash-burn levels, the business has not yet demonstrated self-funding operations. Continued negative operating and free cash flow can require external funding, potentially diluting shareholders or increasing financial pressure before positive cash generation is achieved.
Sonendo News
SONX FAQ
What was Sonendo’s price range in the past 12 months?
Sonendo lowest stock price was $0.02 and its highest was $1.01 in the past 12 months.
What is Sonendo’s market cap?
Sonendo’s market cap is $235.07K.
When is Sonendo’s upcoming earnings report date?
Sonendo’s upcoming earnings report date is Mar 23, 2027 which is in 218 days.
How were Sonendo’s earnings last quarter?
Currently, no data Available
Is Sonendo overvalued?
According to Wall Street analysts Sonendo’s price is currently Overvalued.
Does Sonendo pay dividends?
Sonendo does not currently pay dividends.
What is Sonendo’s EPS estimate?
Sonendo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonendo have?
Sonendo has 427,401 shares outstanding.
What happened to Sonendo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sonendo?
Currently, no hedge funds are holding shares in SONX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonendo
Sonendo, Inc. operates as a commercial-stage medical technology firm, dedicated to innovating, producing, and marketing advanced devices for root canal treatment across the United States and Canada. A flagship offering is GentleWave, an innovative device for addressing tooth decay that meticulously cleans and sanitizes the intricate microscopic passages within teeth without the need for removing any natural tooth structure. The company's product line also features SoundSeal, a specialized material used to construct and seal dental crowns, alongside its proprietary Sonendo-branded liquid solution of EDTA, which assists in the debridement and disinfection processes crucial for root canal systems. Furthermore, Sonendo provides "The Digital Office," a comprehensive practice management software solution designed to foster an integrated digital environment for dental professionals. Established in 2006, the organization was initially known as Dentatek Corporation before officially rebranding to Sonendo, Inc. in March 2011. Its corporate headquarters are situated in Laguna Hills, California.
Technical Analysis
Ownership Overview
―
Insiders
1.08% Mutual Funds
― Other Institutional Investors
98.92% Public Companies and
Individual Investors